ArticleNeurochemical research2021
Sinensetin Attenuates Amyloid Beta
Article in Neurochemical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Sinensetin attenuates post-stroke depression via dual modulation of TLR4/NF-κB-NRF2/GPX4 pathways.Scientific reports · 2026Article
- Article
- Review
- Sinensetin ameliorates established high-fat diet-induced liver injury and intestinal barrier dysfunction through the mitophagy/TLR4/MAPK signaling pathway.Frontiers in nutrition · 2026Article
- Mechanistic study on ligustilide modulation of the TLR4/NF-κB pathway in ameliorating Scopolamine-Induced cognitive impairment.Metabolic brain disease · 2025Article
- Sinensetin attenuates hepatic ischemia-reperfusion injury through suppressing GRP78/CHOP-mediated endoplasmic reticulum (ER) stress in mice.Frontiers in pharmacology · 2025Article
- Sinensetin Attenuated Macrophagic NLRP3 Inflammasomes FormationACS omega · 2023Article
- A Combination of Polymethoxyflavones fromAntioxidants (Basel, Switzerland) · 2023Article
- From Plants to Psycho-Neurology: Unravelling the Therapeutic Benefits of Bioactive Compounds in Brain Disorders.Antioxidants (Basel, Switzerland) · 2023Review
- The neuroprotective effects of the combined extract of mulberry fruit and mulberry leaf against hydrogen peroxide-induced cytotoxicity in SH-SY5Y Cells.BMC complementary medicine and therapies · 2023Article
- Research Progress on the Pharmacodynamic Mechanisms of Sini Powder against Depression from the Perspective of the Central Nervous System.Medicina (Kaunas, Lithuania) · 2023Review
- Plant-Derived Bioactive Compounds in the Management of Neurodegenerative Disorders: Challenges, Future Directions and Molecular Mechanisms Involved in Neuroprotection.Pharmaceutics · 2023Review
- VANL-100 Attenuates Beta-Amyloid-Induced Toxicity in SH-SY5Y Cells.International journal of molecular sciences · 2022Article
- The Chemistry and the Anti-Inflammatory Activity of Polymethoxyflavonoids fromAntioxidants (Basel, Switzerland) · 2022Review
- Toll-Like Receptor 4: A Promising Therapeutic Target for Alzheimer's Disease.Mediators of inflammation · 2022Review
- Strategies for Biomaterial-Based Spinal Cord Injury RepairFrontiers in bioengineering and biotechnology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sinensetin (SIN) is an important active compound that exists widely in citrus plants, and has been reported to exhibit various pharmacological properties, including anti-oxidative, anti-inflammatory, and anti-tumor. This study was designed to examine whether SIN can protect against amyloid beta (Aβ)-induced neurotoxicity and to elucidate the underlying mechanism. Our results showed that pretreatment with SIN for 1 h, followed by co-treatment with Aβ plus SIN for 24 h, attenuated Aβ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.